• Biome achieves another record in quarterly sales revenue of ~$4.6m for Q2
• First half sales revenue reaches ~$8.9m for H1 FY25, up 48.3% vs H1 FY24
• Biome achieves a compounded annual growth rate (CAGR) of 70.5% for the three years ending 31 December 2024

Biome Australia Limited (ASX: BIO), a microbiome health company, has reported another record in quarterly sales revenue of ~$4.6m for Q2 FY25, representing a ~$100k increase on the market forecast ($4.5m) shared on 27 November 2024. Biome's Q2 sales revenue represents an annualised run rate of $18.4m. The company's first half sales revenue reached ~$8.9m for H1 FY25, up 48.3% compared to H1 FY24. Biome has achieved a compounded annual growth rate (CAGR) of 70.5% for the three years ending 31 December 2024. Strong growth is expected to continue throughout the remainder of FY25, with the second half of the financial year being the strongest seasonal sales period for Biome. The company is now working on longer-term growth metrics, with the aim of achieving the top end of the revenue range of Vision 27 ($85m cumulative sales for FY25-27), which would require a CAGR of ~45% over the three-year period.

Biome's Q2 sales revenue represents an annualised run rate of $18.4m. To achieve the top end of the revenue range of Vision 27 ($85m cumulative sales for FY25-27), Biome needs to achieve a CAGR of ~45% over the three-year period.

Strong growth is expected to continue throughout the remainder of FY25, with the second half of the financial year being the strongest seasonal sales period for Biome. Biome is now working on longer-term growth metrics to achieve the top end of the revenue range of Vision 27 ($85m cumulative sales for FY25-27).